DOCSLIB.ORG

Vote Summary Report Reporting Period: 07/01/2018 to 06/30/2019 Institution Account(S): Epoch Global Shareholder Yield Fund

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vote Summary Report Reporting Period: 07/01/2018 to 06/30/2019 Institution Account(S): Epoch Global Shareholder Yield Fund Vote Summary Report Reporting Period: 07/01/2018 to 06/30/2019 Institution Account(s): Epoch Global Shareholder Yield Fund Nutrien Ltd. Meeting Date: 07/19/2018 Country: Canada Primary Security ID: 67077M108 Record Date: 06/06/2018 Meeting Type: Annual Ticker: NTR Primary CUSIP: 67077M108 Primary ISIN: CA67077M1086 Primary SEDOL: BDRJLN0 Vote Proposal Votable Vote Against Number Proposal Text Proponent Proposal Mgmt Rec Instruction Mgmt 1.1 Elect Director Christopher M. Burley Mgmt Yes For For No 1.2 Elect Director Maura J. Clark Mgmt Yes For For No 1.3 Elect Director John W. Estey Mgmt Yes For For No 1.4 Elect Director David C. Everitt Mgmt Yes For For No 1.5 Elect Director Russell K. Girling Mgmt Yes For For No 1.6 Elect Director Gerald W. Grandey Mgmt Yes For For No 1.7 Elect Director Miranda C. Hubbs Mgmt Yes For For No 1.8 Elect Director Alice D. Laberge Mgmt Yes For For No 1.9 Elect Director Consuelo E. Madere Mgmt Yes For For No 1.10 Elect Director Charles "Chuck" V. Magro Mgmt Yes For For No 1.11 Elect Director Keith G. Martell Mgmt Yes For For No 1.12 Elect Director A. Anne McLellan Mgmt Yes For For No 1.13 Elect Director Derek G. Pannell Mgmt Yes For For No 1.14 Elect Director Aaron W. Regent Mgmt Yes For For No 1.15 Elect Director Mayo M. Schmidt Mgmt Yes For For No 1.16 Elect Director Jochen E. Tilk Mgmt Yes For For No 2 Approve Re-appointment of KPMG LLP as Mgmt Yes For For No Auditors 3 Approve Stock Option Plan and Grant of Stock Mgmt Yes For For No Options 4 Advisory Vote on Executive Compensation Mgmt Yes For For No Approach SSE plc Meeting Date: 07/19/2018 Country: United Kingdom Primary Security ID: G8842P102 Record Date: 07/17/2018 Meeting Type: Annual Ticker: SSE Primary CUSIP: G7885V109 Primary ISIN: GB0007908733 Primary SEDOL: 0790873 Page 1 of 92 Vote Summary Report Reporting Period: 07/01/2018 to 06/30/2019 Institution Account(s): Epoch Global Shareholder Yield Fund SSE plc Vote Proposal Votable Vote Against Number Proposal Text Proponent Proposal Mgmt Rec Instruction Mgmt 1 Accept Financial Statements and Statutory Mgmt Yes For For No Reports 2 Approve Remuneration Report Mgmt Yes For For No 3 Approve Final Dividend Mgmt Yes For For No 4 Re-elect Gregor Alexander as Director Mgmt Yes For For No 5 Re-elect Sue Bruce as Director Mgmt Yes For For No 6 Elect Tony Cocker as Director Mgmt Yes For For No 7 Re-elect Crawford Gillies as Director Mgmt Yes For For No 8 Re-elect Richard Gillingwater as Director Mgmt Yes For For No 9 Re-elect Peter Lynas as Director Mgmt Yes For For No 10 Re-elect Helen Mahy as Director Mgmt Yes For For No 11 Re-elect Alistair Phillips-Davies as Director Mgmt Yes For For No 12 Elect Martin Pibworth as Director Mgmt Yes For For No 13 Reappoint KPMG LLP Auditors Mgmt Yes For For No 14 Authorise Audit Committee to Fix Mgmt Yes For For No Remuneration of Auditors 15 Authorise Issue of Equity with Pre-emptive Mgmt Yes For For No Rights 16 Authorise Issue of Equity without Pre-emptive Mgmt Yes For For No Rights 17 Authorise Market Purchase of Ordinary Shares Mgmt Yes For For No 18 Approve Scrip Dividend Scheme Mgmt Yes For For No 19 Authorise the Company to Call General Mgmt Yes For For No Meeting with Two Weeks' Notice SSE plc Meeting Date: 07/19/2018 Country: United Kingdom Primary Security ID: G8842P102 Record Date: 07/17/2018 Meeting Type: Special Ticker: SSE Primary CUSIP: G7885V109 Primary ISIN: GB0007908733 Primary SEDOL: 0790873 Page 2 of 92 Vote Summary Report Reporting Period: 07/01/2018 to 06/30/2019 Institution Account(s): Epoch Global Shareholder Yield Fund SSE plc Vote Proposal Votable Vote Against Number Proposal Text Proponent Proposal Mgmt Rec Instruction Mgmt i Approve the Declaration of a Special Dividend Mgmt Yes For For No to give effect to the Demerger of SSE Energy Services from SSE ii Approve Waiver on Tender-Bid Requirement Mgmt Yes For For No Singapore Telecommunications Limited Meeting Date: 07/24/2018 Country: Singapore Primary Security ID: Y79985209 Record Date: Meeting Type: Annual Ticker: Z74 Primary CUSIP: Y79985209 Primary ISIN: SG1T75931496 Primary SEDOL: B02PY22 Vote Proposal Votable Vote Against Number Proposal Text Proponent Proposal Mgmt Rec Instruction Mgmt 1 Adopt Financial Statements and Directors' and Mgmt Yes For For No Auditors' Reports 2 Approve Final Dividend Mgmt Yes For For No 3 Elect Bobby Chin Yoke Choong as Director Mgmt Yes For For No 4 Elect Venkataraman Vishnampet Ganesan as Mgmt Yes For For No Director 5 Elect Teo Swee Lian as Director Mgmt Yes For For No 6 Elect Gautam Banerjee as Director Mgmt Yes For For No 7 Approve Directors' Fees Mgmt Yes For For No 8 Approve KPMG LLP as Auditors and Authorize Mgmt Yes For For No Board to Fix Their Remuneration 9 Approve Issuance of Equity or Equity-Linked Mgmt Yes For For No Securities with or without Preemptive Rights 10 Approve Grant of Awards and Issuance of Mgmt Yes For For No Shares Under the Singtel Performance Share Plan 2012 11 Authorize Share Repurchase Program Mgmt Yes For For No Page 3 of 92 Vote Summary Report Reporting Period: 07/01/2018 to 06/30/2019 Institution Account(s): Epoch Global Shareholder Yield Fund Macquarie Group Limited Meeting Date: 07/26/2018 Country: Australia Primary Security ID: Q57085286 Record Date: 07/24/2018 Meeting Type: Annual Ticker: MQG Primary CUSIP: Q57085104 Primary ISIN: AU000000MQG1 Primary SEDOL: B28YTC2 Vote Proposal Votable Vote Against Number Proposal Text Proponent Proposal Mgmt Rec Instruction Mgmt 2a Elect Peter H Warne as Director Mgmt Yes For For No 2b Elect Gordon M Cairns as Director Mgmt Yes For For No 2c Elect Glenn R Stevens as Director Mgmt Yes For For No 3 Approve the Remuneration Report Mgmt Yes For For No 4 Approve Participation of Nicholas Moore in Mgmt Yes For For No the Macquarie Group Employee Retained Equity Plan 5 Approve Issuance of Macquarie Group Capital Mgmt Yes For For No Notes Vodafone Group Plc Meeting Date: 07/27/2018 Country: United Kingdom Primary Security ID: G93882192 Record Date: 07/25/2018 Meeting Type: Annual Ticker: VOD Primary CUSIP: G93882135 Primary ISIN: GB00BH4HKS39 Primary SEDOL: BH4HKS3 Vote Proposal Votable Vote Against Number Proposal Text Proponent Proposal Mgmt Rec Instruction Mgmt 1 Accept Financial Statements and Statutory Mgmt Yes For For No Reports 2 Elect Michel Demare as Director Mgmt Yes For For No 3 Elect Margherita Della Valle as Director Mgmt Yes For For No 4 Re-elect Gerard Kleisterlee as Director Mgmt Yes For For No 5 Re-elect Vittorio Colao as Director Mgmt Yes For For No 6 Re-elect Nick Read as Director Mgmt Yes For For No 7 Re-elect Sir Crispin Davis as Director Mgmt Yes For For No 8 Re-elect Dame Clara Furse as Director Mgmt Yes For For No 9 Re-elect Valerie Gooding as Director Mgmt Yes For For No 10 Re-elect Renee James as Director Mgmt Yes For For No Page 4 of 92 Vote Summary Report Reporting Period: 07/01/2018 to 06/30/2019 Institution Account(s): Epoch Global Shareholder Yield Fund Vodafone Group Plc Vote Proposal Votable Vote Against Number Proposal Text Proponent Proposal Mgmt Rec Instruction Mgmt 11 Re-elect Samuel Jonah as Director Mgmt Yes For For No 12 Re-elect Maria Amparo Moraleda Martinez as Mgmt Yes For For No Director 13 Re-elect David Nish as Director Mgmt Yes For For No 14 Approve Final Dividend Mgmt Yes For For No 15 Approve Remuneration Report Mgmt Yes For For No 16 Reappoint PricewaterhouseCoopers LLP as Mgmt Yes For For No Auditors 17 Authorise the Audit and Risk Committee to Fix Mgmt Yes For For No Remuneration of Auditors 18 Authorise Issue of Equity with Pre-emptive Mgmt Yes For For No Rights 19 Authorise Issue of Equity without Pre-emptive Mgmt Yes For For No Rights 20 Authorise Issue of Equity without Pre-emptive Mgmt Yes For For No Rights in Connection with an Acquisition or Other Capital Investment 21 Authorise Market Purchase of Ordinary Shares Mgmt Yes For For No 22 Authorise EU Political Donations and Mgmt Yes For For No Expenditure 23 Authorise the Company to Call General Mgmt Yes For For No Meeting with Two Weeks' Notice 24 Approve Sharesave Plan Mgmt Yes For For No 25 Adopt New Articles of Association Mgmt Yes For For No National Grid plc Meeting Date: 07/30/2018 Country: United Kingdom Primary Security ID: G6S9A7120 Record Date: 07/28/2018 Meeting Type: Annual Ticker: NG. Primary CUSIP: G6375K151 Primary ISIN: GB00BDR05C01 Primary SEDOL: BDR05C0 Vote Proposal Votable Vote Against Number Proposal Text Proponent Proposal Mgmt Rec Instruction Mgmt 1 Accept Financial Statements and Statutory Mgmt Yes For For No Reports 2 Approve Final Dividend Mgmt Yes For For No 3 Re-elect Sir Peter Gershon as Director Mgmt Yes For For No Page 5 of 92 Vote Summary Report Reporting Period: 07/01/2018 to 06/30/2019 Institution Account(s): Epoch Global Shareholder Yield Fund National Grid plc Vote Proposal Votable Vote Against Number Proposal Text Proponent Proposal Mgmt Rec Instruction Mgmt 4 Re-elect John Pettigrew as Director Mgmt Yes For For No 5 Re-elect Dean Seavers as Director Mgmt Yes For For No 6 Re-elect Nicola Shaw as Director Mgmt Yes For For No 7 Re-elect Nora Brownell as Director Mgmt Yes For For No 8 Re-elect Jonathan Dawson as Director Mgmt Yes For For No 9 Re-elect Therese Esperdy as Director Mgmt Yes For For No 10 Re-elect Paul Golby as Director Mgmt Yes For For No 11 Re-elect Mark Williamson as Director Mgmt Yes For For No 12 Elect Amanda Mesler as Director Mgmt Yes For For No 13 Reappoint Deloitte LLP as Auditors Mgmt Yes For For No 14 Authorise Board to Fix Remuneration of Mgmt Yes For For No Auditors 15 Approve Remuneration Report Mgmt Yes
Load more

Recommended publications
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* GENOCEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, Par Value $0.001 (Title of Class of Securities) 372427 10 4 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 30, 2015 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
    [Show full text]
  • Corporate Governance
    Strategic report Governance and remuneration Financial statements Investor information Corporate Governance In this section Chairman’s Governance statement 78 The Board 80 Corporate Executive Team 83 Board architecture 85 Board roles and responsibilities 86 Board activity and principal decisions 87 Our purpose, values and culture 90 The Board’s approach to engagement 91 Board performance 94 Board Committee information 96 Our Board Committee reports 97 Section 172 statement 108 Directors’ report 109 GSK Annual Report 2020 77 Chairman’s Governance statement In last year’s Governance statement, I explained that our primary Education and focus on Science objective for 2020 was to ensure there was clarity between the Given the critical importance of strengthening the pipeline, Board and management on GSK’s execution of strategy and its the Board has benefitted from devoting a higher proportion of operational priorities. We have aligned our long-term priorities its time in understanding the science behind our strategy and of Innovation, Performance and Trust powered by culture testing its application. It is important that the Board has a and agreed on the metrics to measure delivery against them. working understanding of the key strategic themes upon The Board’s annual cycle of meetings ensures that all major which our R&D strategy is based. These themes have been components of our strategy are reviewed over the course complemented by Board R&D science thematic deep dives. of the year. Our focus was on the fundamentals of our strategy: human The COVID-19 pandemic impacted and dominated all our genetics, the immune system and AI and ML, as well as to lives for the majority of 2020.
    [Show full text]
  • Governance and Remuneration 2014
    Governance & remuneration reportStrategic In this section Our Board 72 Our Corporate Executive Team 76 Chairman’s letter 78 Corporate governance framework 79 Board report to shareholders Oversight and stewardship in 2014 and future actions 80 remuneration & Governance Leadership and effectiveness 82 Committee reports Audit & Risk 86 Nominations 92 Corporate Responsibility 94 Remuneration report Chairman’s annual statement 96 Annual report on remuneration 97 2014 Remuneration policy report 119 Financial statements Financial Investor information Investor GSK Annual Report 2014 71 Our Board Strategic reportStrategic Diversity Experience International experience Composition Tenure (Non-Executives) % % % % Scientific 19 Global 75 Executive 19 Up to 3 years 39 % % % % Finance 31 USA 100 Non-Executive 81 3-6 years 15 % % % % Industry 50 Europe 94 Male 69 7-9 years 23 % % % EMAP 63 Female 31 Over 9 years 23 Sir Christopher Gent 66 Skills and experience Chairman Sir Christopher has many years of experience of leading global businesses and a track record of delivering outstanding performance Governance & remuneration & Governance Nationality in highly competitive industries. He was appointed Managing Director British of Vodafone plc in 1985 and then became its Chief Executive Officer Appointment date in 1997 until his retirement in 2003. Sir Christopher was also a 1 June 2004 and as Chairman Non-Executive Director of Ferrari SpA and a member of the British on 1 January 2005 Airways International Business Advisory Board. Committee membership External appointments Corporate Responsibility Sir Christopher is a Senior Adviser at Bain & Co. Committee Chairman, Nominations, Remuneration and Finance Sir Philip Hampton 61 Skills and experience Chairman Designate Prior to joining GSK, Sir Philip chaired major FTSE 100 companies including J Sainsbury plc.
    [Show full text]
  • MORPHIC HOLDING, INC. (Name of Issuer)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) MORPHIC HOLDING, INC. (Name of Issuer) Common Stock, Par Value $0.0001 (Title of Class of Securities) 61775R 10 5 (CUSIP Number) Victoria A. Whyte GlaxoSmithKline plc 980 Great West Road Brentford, Middlesex TW8 9GS England Telephone: +44 (0)208 047 5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 23, 2020 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐ Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
    [Show full text]
  • Annual Report of Proxy Voting Record Date
    ANNUAL REPORT OF PROXY VOTING RECORD DATE OF REPORTING PERIOD: JULY 1, 2018 - JUNE 30, 2019 FUND: VANGUARD FTSE 100 UCITS ETF --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ISSUER: 3i Group Plc TICKER: III CUSIP: G88473148 MEETING DATE: 6/27/2019 FOR/AGAINST PROPOSAL: PROPOSED BY VOTED? VOTE CAST MGMT PROPOSAL #1: ACCEPT FINANCIAL STATEMENTS AND ISSUER YES FOR FOR STATUTORY REPORTS PROPOSAL #2: APPROVE REMUNERATION REPORT ISSUER YES FOR FOR PROPOSAL #3: APPROVE FINAL DIVIDEND ISSUER YES FOR FOR PROPOSAL #4: RE-ELECT JONATHAN ASQUITH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #5: RE-ELECT CAROLINE BANSZKY AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #6: RE-ELECT SIMON BORROWS AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #7: RE-ELECT STEPHEN DAINTITH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #8: RE-ELECT PETER GROSCH AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #9: RE-ELECT DAVID HUTCHISON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #10: ELECT COLINE MCCONVILLE AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #11: RE-ELECT SIMON THOMPSON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #12: RE-ELECT JULIA WILSON AS DIRECTOR ISSUER YES FOR FOR PROPOSAL #13: REAPPOINT ERNST & YOUNG LLP AS AUDITORS ISSUER YES FOR FOR PROPOSAL #14: AUTHORISE BOARD ACTING THROUGH THE ISSUER YES FOR FOR AUDIT AND COMPLIANCE COMMITTEE TO FIX REMUNERATION OF AUDITORS PROPOSAL #15: AUTHORISE EU POLITICAL DONATIONS AND ISSUER YES FOR FOR EXPENDITURE PROPOSAL #16: AUTHORISE ISSUE
    [Show full text]
  • Annual Report 2013
    Annual Report 2013 “ Being active and having a positive outlook on life is what keeps me going every day.” Overview of 2013 “ Our performance in 2013 was defined by remarkable &R D output and further delivery of sustained financial performance for our shareholders.” Please go to page 4 for more More at gsk.com Performance highlights £26.5bn £8.0bn £7.0bn £5.2bn Group turnover Core* operating profit Total operating profit Returned to shareholders 6 112.2p 112.5p 13% Major medicines approved Core* earnings per share Total earnings per share Estimated return on R&D investment 10 6 1st 1st Potential phase III study starts in 2014/15 Potential medicines with phase III data in Access to Medicines Index Pharmaceutical company to sign AllTrials expected 2014/15 campaign for research transparency Front cover story Betty, aged 65, (pictured) has Chronic “ Health is important to me, Obstructive Pulmonary Disease (COPD). She only has 25% lung capacity. This means I try to take care of my she finds even everyday tasks difficult, but medicines and inhaled oxygen allow her to health with all the tools live as normal a life as she can. Betty’s mindset I have and do the best is to stay busy and active, so every week she goes to rehab exercise classes. that I can with it.” COPD is a disease of the lungs that leads to Betty, COPD patient, damaged airways, causing them to become North Carolina, USA narrower and making it harder for air to get in and out. 210 million people around the world are estimated to have COPD.
    [Show full text]
  • 2021 Annual General Meeting Dick Auchinleck Chair of the Board Welcome to the 2021 Annual General Meeting
    2021 annual general meeting Dick Auchinleck Chair of the Board Welcome to the 2021 annual general meeting Keeping people connected Leading the world in social capitalism Commitment to diversity ● First adopted our Board diversity policy in 2013 ● Women and men to each represent 33⅓% of independent directors ● At least two directors who represent a visible minority or are Indigenous by 2023 AGM Darren Entwistle President and CEO, TELUS Andrea Wood Chief Legal and Governance Officer Christopher Main Associate General Counsel and Assistant Corporate Secretary Caution regarding forward-looking statements Caution regarding forward-looking statements Today’s discussion may contain forward-looking statements, including statements relating to our objectives and strategies, our targets, outlook, updates, our plans and expectations regarding the impact of the COVID-19 pandemic and responses to it, and our multi-year dividend growth program. Forward-looking statements use words such as assumption, goal, guidance, objective, outlook, strategy, target and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, could, expect, intend, may, plan, predict, seek, should, strive and will. Forward-looking statements are subject to inherent risks and uncertainties (such as the impact of the COVID-19 pandemic and responses to it, regulatory decisions and developments, the performance of the Canadian and provincial economies, the competitive environment, the impact of technological substitution, challenges in deploying technology, our earnings and free cash flow, and our capital expenditures), and are based on assumptions, including about future economic conditions and courses of action. These assumptions may ultimately prove inaccurate and, as a result, our actual results or events may differ materially from expectations expressed today.
    [Show full text]
  • Annual Review 2005
    GS2184_Review_A\W2.qxd 7/3/06 4:58 pm Page fc1 Annual Review 2005 human being Do more, feel better, live longer GS2184_Review_A\W2.qxd 9/3/06 1:28 pm Page ifc2 01 An interview with Sir Christopher Gent, Chairman, and JP Garnier, Chief Executive Officer 05 Tachi Yamada, Chairman, Research & Development, Pharmaceuticals 06 Jean Stéphenne, President and General Manager, GSK Biologicals 08 John Clarke, President, Consumer Healthcare 11 David Stout, President, Pharmaceutical Operations 14 Performance highlights 15 Business operating review 18 The Board 19 The Corporate Executive Team 20 Summary remuneration report 23 Corporate governance 24 Responsibility statements 25 Summary financial statements 26 Summary information under US GAAP 27 Shareholder information 29 Chairman and CEO’s closing letter JP Garnier (left) and Sir Christopher Gent (right) GS2184_Review_A\W2.qxd 7/3/06 5:01 pm Page 01 “Discovering important medicines, eradicating diseases, improving the quality of people’s lives and making medicines available to a greater number of people. This is what we do – and what we do matters to people.” JP Garnier, Chief Executive Officer An interview with Sir Christopher Gent, Chairman and JP Garnier, Chief Executive Officer 2005: a year of success and progress “Thanks to the efforts of our employees around the company’s pipeline is one of the largest and most world, 2005 was a very successful year for GSK,” says promising in the industry, with 149 projects in clinical JP Garnier, Chief Executive Officer. “Not only was it development (as at the end of February 2006), our best year ever from a financial standpoint, we also including 95 new chemical entities (NCEs), 29 product made substantial progress with our pipeline of line extensions (PLEs) and 25 vaccines.
    [Show full text]
  • Mainstay VP Income Builder Portfolio Proxy Voting Record
    MainStay VP Income Builder Portfolio ******************************* FORM N-Px REPORT ******************************* ICA File Number: 811-03833 Reporting Period: 07/01/2020 - 06/30/2021 MainStay VP Funds Trust ===================== MainStay VP Income Builder Portfolio ===================== ABBVIE INC. Ticker: ABBV Security ID: 00287Y109 Meeting Date: MAY 07, 2021 Meeting Type: Annual Record Date: MAR 08, 2021 # Proposal Mgt Rec Vote Cast Sponsor 1.1 Elect Director Roxanne S. Austin For For Management 1.2 Elect Director Richard A. Gonzalez For For Management 1.3 Elect Director Rebecca B. Roberts For For Management 1.4 Elect Director Glenn F. Tilton For For Management 2 Ratify Ernst & Young LLP as Auditors For For Management 3 Advisory Vote to Ratify Named For For Management Executive Officers' Compensation 4 Amend Omnibus Stock Plan For For Management 5 Amend Nonqualified Employee Stock For For Management Purchase Plan 6 Eliminate Supermajority Vote For For Management Requirement 7 Report on Lobbying Payments and Policy Against For Shareholder 8 Require Independent Board Chair Against Against Shareholder -------------------------------------------------------------------------------- ALLIANZ SE Ticker: ALV Security ID: D03080112 Meeting Date: MAY 05, 2021 Meeting Type: Annual Record Date: # Proposal Mgt Rec Vote Cast Sponsor 1 Receive Financial Statements and None None Management Statutory Reports for Fiscal Year 2020 (Non-Voting) 2 Approve Allocation of Income and For Did Not Vote Management Dividends of EUR 9.60 per Share 3 Approve Discharge of Management Board For Did Not Vote Management for Fiscal Year 2020 4 Approve Discharge of Supervisory Board For Did Not Vote Management for Fiscal Year 2020 5 Approve Remuneration Policy For Did Not Vote Management 6 Approve Remuneration of Supervisory For Did Not Vote Management Board 7 Amend Articles Re: Supervisory Board For Did Not Vote Management Term of Office Page 1 MainStay VP Income Builder Portfolio -------------------------------------------------------------------------------- ALTRIA GROUP, INC.
    [Show full text]
  • Registre Des Votes Par Procuration
    Registre des votes par procuration pour l’exercice clos le 30 juin 2020 Fonds mondial de gestion de la volatilité Registre des votes par procuration © SEI 2020 seic.com/fr-ca global_2020.txt ******************************* FORM N‐Px REPORT ******************************* Fund Name : GLOBAL MANAGED VOLATILITY FUND _______________________________________________________________________________ AEON REIT Investment Corporation Ticker Security ID: Meeting Date Meeting Status 3292 CINS J10006104 10/17/2019 Voted Meeting Type Country of Trade Special Japan Issue No. Description Proponent Mgmt Rec Vote Cast For/Against Mgmt 1 Elect Nobuaki Seki as Mgmt For For For Executive Director 2 Elect Tetsuya Arisaka Mgmt For For For 3 Elect Akifumi Togawa Mgmt For For For 4 Elect Chiyu Abo Mgmt For For For 5 Elect Yoko Seki Mgmt For For For ________________________________________________________________________________ Aflac Incorporated Ticker Security ID: Meeting Date Meeting Status AFL CUSIP 001055102 05/04/2020 Voted Meeting Type Country of Trade Annual United States Issue No. Description Proponent Mgmt Rec Vote Cast For/Against Mgmt 1 Elect Daniel P. Amos Mgmt For For For 2 Elect W. Paul Bowers Mgmt For For For 3 Elect Toshihiko Mgmt For For For Fukuzawa 4 Elect Thomas J. Kenny Mgmt For For For 5 Elect Georgette D. Mgmt For For For Kiser 6 Elect Karole F. Lloyd Mgmt For For For 7 Elect Nobuchika Mori Mgmt For For For 8 Elect Joseph L. Mgmt For For For Moskowitz 9 Elect Barbara K. Rimer Mgmt For For For 10 Elect Katherine T. Mgmt For For For Rohrer Page 1 global_2020.txt 11 Elect Melvin T. Stith Mgmt For For For 12 Advisory Vote on Mgmt For For For Executive Compensation 13 Ratification of Auditor Mgmt For Against Against ________________________________________________________________________________ Ageas SA/NV Ticker Security ID: Meeting Date Meeting Status AGS CINS B0148L138 04/23/2020 Voted Meeting Type Country of Trade Special Belgium Issue No.
    [Show full text]
  • In This Section
    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
    [Show full text]
  • Voting/Poll Results
    GLAXOSMITHKLINE PLC - RESULT OF AGM GlaxoSmithKline plc (GSK) announces that at its Annual General Meeting (AGM) today, all resolutions were passed by shareholders. GlaxoSmithKline AGM Poll Results The following table shows the votes cast for each resolution: Resolution Total votes % Total votes % Total votes Votes for* against cast withheld** Adoption of Directors’ 1 Report and Financial Statements 3,713,877,875 98.86 42,764,532 1.14 3,756,642,407 9,313,386 Approval of the 2 Remuneration Report 3,528,115,173 94.55 203,482,136 5.45 3,731,597,309 34,358,483 Election of 3 Lynn Elsenhans 3,753,666,422 99.90 3,577,765 0.10 3,757,244,187 8,711,607 Election of 4 Jing Ulrich 3,753,601,642 99.90 3,623,347 0.10 3,757,224,989 8,730,805 Election of 5 Hans Wijers 3,712,833,757 98.82 44,327,830 1.18 3,757,161,587 8,794,257 Re-election of Sir 6 Christopher Gent 3,679,075,355 97.92 78,304,492 2.08 3,757,379,847 8,575,946 Re-election of 7 Sir Andrew Witty 3,753,850,300 99.90 3,750,413 0.10 3,757,600,713 8,355,081 Re-election of Professor Sir 8 Roy Anderson 3,753,929,716 99.91 3,483,857 0.09 3,757,413,573 8,542,221 Re-election of 9 Dr Stephanie Burns 3,749,134,033 99.78 8,228,665 0.22 3,757,362,698 8,592,951 Re-election of 10 Stacey Cartwright 3,735,971,985 99.43 21,360,372 0.57 3,757,332,357 8,623,292 Re-election of 11 Simon Dingemans 3,749,800,702 99.80 7,359,374 0.20 3,757,160,076 8,795,718 Re-election of 12 Judy Lewent 3,746,232,485 99.71 11,060,403 0.29 3,757,292,888 8,662,906 Re-election of 13 Sir Deryck Maughan 3,748,191,348 99.76 9,051,199 0.24
    [Show full text]